Paperpal Prime Logo

Therapeutic Advances in Musculoskeletal Disease : Impact Factor & More

eISSN: 1759-7218pISSN: 1759-720X
JournalOpen Access

Key Metrics

CiteScore
3.7
H-Index
44
Impact Factor
< 5
SJR
Q1Rheumatology
SNIP
1.17
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Therapeutic Advances in Musculoskeletal Disease

Therapeutic Advances in Musculoskeletal Disease Journal Specifications

Overview
Publisher SAGE PUBLICATIONS LTD
Language English
Frequency Continuous publication
Article Processing ChargesUSD 2300
Publication Time18
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2009
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 18
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC
OA statementVisit website
View less

Planning to publish in Therapeutic Advances in Musculoskeletal Disease ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Therapeutic Advances in Musculoskeletal Disease

Therapeutic management of axial spondyloarthritis: summary of 2024 update of the Spanish clinical practice guideline (ESPOGUIA)
  • 1 Aug 2026
  • Therapeutic Advances in Musculoskeletal Disease
Clinical spectrum and outcomes of mononeuritis multiplex in rheumatic diseases: evidence from a nationwide multicenter study
  • 1 Aug 2026
  • Therapeutic Advances in Musculoskeletal Disease
Recurrent uveitis unveiling axial spondyloarthritis: is inflammatory back pain always the main road to diagnosis? A monocentric cohort
  • 1 Aug 2026
  • Therapeutic Advances in Musculoskeletal Disease
MCCs in adults with autoimmune and inflammatory rheumatic diseases: evidence to date and future directions
  • 25 Jul 2026
  • Therapeutic Advances in Musculoskeletal Disease
Longitudinal osteoporosis therapy: treat-to-target and sequential strategies\u2014a narrative review
  • 21 Jul 2026
  • Therapeutic Advances in Musculoskeletal Disease
Cardiometabolic disease and risk of total knee arthroplasty among patients with knee osteoarthritis receiving intra-articular hyaluronic acid: a real-world cohort study
  • 20 Jul 2026
  • Therapeutic Advances in Musculoskeletal Disease
Therapeutic management of axial spondyloarthritis: summary of 2024 update of the Spanish clinical practice guideline (ESPOGUIA)
  • 1 Aug 2026
  • Therapeutic Advances in Musculoskeletal Disease
Clinical spectrum and outcomes of mononeuritis multiplex in rheumatic diseases: evidence from a nationwide multicenter study
  • 1 Aug 2026
  • Therapeutic Advances in Musculoskeletal Disease
Recurrent uveitis unveiling axial spondyloarthritis: is inflammatory back pain always the main road to diagnosis? A monocentric cohort
  • 1 Aug 2026
  • Therapeutic Advances in Musculoskeletal Disease
MCCs in adults with autoimmune and inflammatory rheumatic diseases: evidence to date and future directions
  • 25 Jul 2026
  • Therapeutic Advances in Musculoskeletal Disease
Longitudinal osteoporosis therapy: treat-to-target and sequential strategies\u2014a narrative review
  • 21 Jul 2026
  • Therapeutic Advances in Musculoskeletal Disease
Cardiometabolic disease and risk of total knee arthroplasty among patients with knee osteoarthritis receiving intra-articular hyaluronic acid: a real-world cohort study
  • 20 Jul 2026
  • Therapeutic Advances in Musculoskeletal Disease

FAQs on Therapeutic Advances in Musculoskeletal Disease